Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 20/20 | 0.58 |
| ▸ | MMP13 | P45452 | 18/20 | 0.58 |
| ▸ | MMP9 | P14780 | 9/20 | 0.58 |
| ▸ | MMP2 | P08253 | 8/20 | 0.58 |
| ▸ | MMP3 | P08254 | 7/20 | 0.58 |
| ▸ | MMP7 | P09237 | 5/20 | 0.58 |
| ▸ | MMP8 | P22894 | 5/20 | 0.58 |
| ▸ | ADAM17 | P78536 | 15/20 | 0.56 |
| ▸ | MMP14 | P50281 | 2/20 | 0.55 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.50 |
| ▸ | ADAM9 | Q13443 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6109667 | 0.87 | MMP1 (0.56) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL5655757 | 0.87 | MMP1 (0.56) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL6429984 | 0.86 | MMP1 (0.63) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL6429978 | 0.86 | MMP1 (0.63) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL6429127 | 0.85 | MMP1 (0.74) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL6429129 | 0.85 | MMP1 (0.74) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL6502760 | 0.84 | MMP1 (0.69) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL6108282 | 0.84 | MMP1 (0.59) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL6755433 | 0.83 | MMP1 (0.75) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL6754057 | 0.82 | MMP1 (0.76) | MMP1MMP13MMP9MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022846-B2 | Metabolites of prinomastat and their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20040053922-A1 | Metabolites of prinomastat and their synthesis | AGOURON PHARMACEUTICALS, INC. | 2004-03-18 | — | — | US | disclosed |
| WO-2003104224-A1 | METABOLITES OF PRINOMASTAT AND THEIR SYTHESIS | PFIZER INC. (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053922-A1 | Metabolites of prinomastat and their synthesis | MMP7, MMP2, MMP3 | MMP1 8/4885MMP13 9/4885MMP9 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.